Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Free Cash Flow (2016 - 2025)

Northwest Biotherapeutics' Free Cash Flow history spans 16 years, with the latest figure at -$15.7 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$15.7 million for Q4 2025, up 22.66% from a year ago — trailing twelve months through Dec 2025 was -$46.3 million (up 20.27% YoY), and the annual figure for FY2025 was -$46.3 million, up 20.27%.
  • Free Cash Flow for Q4 2025 was -$15.7 million at Northwest Biotherapeutics, down from -$14.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$7.0 million in Q2 2025 to a low of -$20.3 million in Q4 2024.
  • The 5-year median for Free Cash Flow is -$12.9 million (2021), against an average of -$13.1 million.
  • The sharpest move saw Free Cash Flow tumbled 83.75% in 2022, then soared 58.18% in 2025.
  • Year by year, Free Cash Flow stood at -$12.8 million in 2021, then grew by 13.99% to -$11.0 million in 2022, then tumbled by 57.83% to -$17.4 million in 2023, then decreased by 16.59% to -$20.3 million in 2024, then grew by 22.66% to -$15.7 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$15.7 million, -$14.1 million, and -$7.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.